Citadel Advisors’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Citadel Advisors’s Portfolio GRTX Stock Details GRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10,300	Closed	-$1.44K	–	15777
2024 Q1	$1.44K	Buy	10,300 +8,100	+368%	+$1.6K	﹤0.01%	14129
2023 Q4	$320	Sell	2,200 -300	-12%	-$47	﹤0.01%	14060
2023 Q3	$438	Sell	2,500 -14,200	-85%	-$17.6K	﹤0.01%	14055
2023 Q2	$52.1K	Sell	16,700 -25,900	-61%	-$77.1K	﹤0.01%	11751
2023 Q1	$109K	Buy	42,600 +11,200	+36%	+$23.1K	﹤0.01%	11127
2022 Q4	$46.8K	Sell	31,400 -99,600	-76%	-$162K	﹤0.01%	12215
2022 Q3	$228K	Sell	131,000 -16,400	-11%	-$23.2K	﹤0.01%	10142
2022 Q2	$192K	Buy	147,400 +23,600	+19%	+$40.4K	﹤0.01%	10741
2022 Q1	$295K	Sell	123,800 -36,000	-23%	-$93.8K	﹤0.01%	10635
2021 Q4	$733K	Buy	+159,800	New	+$528K	﹤0.01%	8722

Other funds holding GRTX

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors's GRTX Position: Q1 2024 in Review

Citadel Advisors sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q1 2024, closing a stake of 590,052 shares — an estimated $116K sold.

Citadel Advisors first reported a position in GRTX in Q1 2022 and held it in 6 quarters. The position peaked at $330K in Q1 2022. 36 funds tracked by Wall St. Rank hold GRTX as of Q1 2024.

Citadel Advisors reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 590,052 Galera Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $116K.
Citadel Advisors first reported a position in Galera Therapeutics, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Citadel Advisors's Galera Therapeutics, Inc. Common Stock position peaked at $330K in Q1 2022.
36 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.